Schedule 13D ownership disclosure
Mineralys Therapeutics Inc
Common Stock · CUSIP: 603170101
Event date: 2025-03-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Samsara BioCapital, L.P.Reported CIK 0001699737
Shares: 5,674,916.00 · Class: 9.0%
- Samsara BioCapital GP, LLCReported CIK 0001888829
Shares: 5,674,916.00 · Class: 9.0%
- Srinivas AkkarajuReported CIK 0001253170
Shares: 5,736,305.00 · Class: 9.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-008276
- Form type
- SCHEDULE 13D/A
- Filer
- Mineralys Therapeutics, Inc.
- CIK
- CIK 1933414
- Filed
- Mar 17, 2025
- Reporting period
- Mar 13, 2025
- Description
- Schedule 13D beneficial ownership